On Wednesday, Disc Medicine earned a positive adjustment to its Relative Strength (RS) Rating, from 78 to 81.
Looking For The Best Stocks To Buy And Watch? Start Here
IBD's unique RS Rating identifies market leadership by showing how a stock's price action over the last 52 weeks compares to that of the other stocks in our database.
Decades of market research reveals that the best stocks often have an 80 or better RS Rating in the early stages of their moves.
Disc Medicine is not currently offering a proper buying opportunity. See if the stock goes on to form a base that could launch a new move.
Disc Medicine reported 0% earnings growth in the latest quarterly report, while sales growth came in at 0%.
Disc Medicine holds the No. 151 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Rigel Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
